Peritoneal mesothelioma: An inusual clinical presentation in a patient without exposure to asbestos;Mesotelioma peritoneal: Una presentación clínica inusual en un paciente sin exposición al asbesto

Anales de Medicina Interna

Volumn 24, Issue 2, 2007, Pages 81-83

  Ponce Lorenzo, J ^a   Gimenez Ortiz A ^a   Aparisi Aparisi, F ^a   Fleitas Kanonnikoff, T ^a   Montalar Salcedo, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Chemotherapy; Cisplatin; Pemetrexed; Peritoneal mesothelioma; PET

Indexed keywords

ASBESTOS; CISPLATIN; PEMETREXED;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG FATALITY; EXPOSURE; HUMAN; INHALATION; MALE; MALIGNANT MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; PERICARDIUM; PERITONEAL CAVITY; PERITONEUM MESOTHELIOMA; PLEURA; PLEURA EFFUSION; POSITRON; SYMPTOMATOLOGY; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUNICA VAGINALIS; FATALITY; MESOTHELIOMA; MIDDLE AGED; PERITONEUM TUMOR;

ASBESTOS; FATAL OUTCOME; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS;

EID: 34548023249     PISSN: 02127199     EISSN: 02127199     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Animan, KH. Natural history and epidemiology of malignant mesotelioma. Chest 1993; 103:373S.
2. Selikoff, IJ, Hammond, EC, Seidman, H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980; 46: 2736.
3. Hansen, J, de Klerk, NH, Musk AW, et al. Environmental exposure to crocidolite and mesothelioma. Exposure-response realationships. Am J Respir Crit Care Med 1998; 157: 69.
4. Doglioni, C, Tos, AP, Laurino, L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996; 20: 1037.
5. Berry, G, Newhouse, ML, Wagner, JC. Mortality from all cancers of asbestos factory workers in east London. 1933-80. Occup Environ Med 2000; 57: 782.
6. Eltabbakh, GH, Piver, MS, Hempling, RE, et al. Clinical Picture, response to therapy, and survival of women with diffuse malignant pritoneal mesotelioma. J Surg Oncol 1999; 70: 6.
7. Labow, DM, Coit, DG, Kelsen, D, et al. Primary peritoneal mesothelioma: how aggressive should we be? Proc Am Soc Clin Oncol 2004; 23: 345a.
8. Loggie, BW, Fleming, RA, McQuellon, RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001; 67: 999.
9. Sugarbaker, PH, Acherman, YI, Gonzalez-Moreno, S, et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol 2002; 29: 51.
10. Janne, PA, Wozniak, AJ, Belani, CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005; 7: 40.
11. Taub, RN, Keohan, ML, Chabot, JC, et al. Peritoneal mesothelioma. Curr Treat Options Oncol 2000; 1: 303.
12. Tsavaris, N, Primikiros, N, Mylonakis, N, et al. Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A retrospective study. Anticancer Res 1997; 17: 3799.
13. Le, DT, Deavers, M, Hunt, K, et al. Cisplatin and irinotecán (CPT-11) for peritoneal mesothelioma. Cancer Invest 2003; 21: 682.